Combining low-dose regorafenib with pembrolizumab as a front-line therapy for patients with MSI-H colorectal cancer: REGPEM-CRC-01.

Authors: Ibrahim Halil Sahin, Ronan Wenhan Hsieh, Pashtoon Murtaza Kasi, Vikram Gorantla, Stacey A. Cohen, John C. Rhee, Rachael A. Safyan, Curtis Tatsuoka, E. Gabriela Chiorean, Patrick M Boland, Richard D. Kim, Mohamedtaki Abdulaziz Tejani, Anwaar Saeed

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps3643

Source: Full article

---

Abstract

TPS3643